TESCO ALLERGY RELIEF

Hayfever Relief Spray for intranasal administration only. The minimum effective dose according to individual response should be used at which the control of symptoms is maintained (200 to 400 micrograms/day), This nasal spray is not recommended for children or adolescents under 18 years of age.

A dosage regimen of two sprays into each nostril morning and evening is recommended. The maximum number of sprays that should be administered each day is 8. Once the symptoms are under control the dosage may be reduced to one spray into each nostril twice a day.

If symptoms have not improved within 14 days, consult your doctor or pharmacist. For full therapeutic benefit, regular use is essential. The co-operation of the patient should be sought to comply with the regular dosage schedule and it should be explained that the maximum relief may not be obtained within the first few doses..

If a dose is missed, then the next dose should be taken when it is due.

Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. Such effects may include hypothalmic-pituitary- adrenal (HPA) suppression and growth retardation in children. Rare cases of nasal septal perforation have been reported following the use of intranasal corticosteroids.

4) have been reported. As with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste and smell and epistaxis have been reported rarely. Very rare cases of hypersensitivity reactions including rashes, urticaria, pruritus and erythema and oedema of the eyes, face, lips and throat, anaphylactoid / anaphylactic reactions, dyspnoea and / or Bronchospasm have been reported Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Nasal passage infections and paranasal sinuses should be appropriately treated. Hayfever Relief Spray may be used in conjunction with other medicaments if required. Medical advice should be sought before using Hayfever Relief 50 micrograms / dose Nasal Spray by patients using other forms of corticosteroid treatments such as asthma medications, tablets, injections, similar nasal sprays, eye or nose drops, creams or ointments.

Caution should be exercised whilst transferring patients from systemic steroid treatment to Hayfever Relief Spray if there is doubt that their adrenal function is impaired. g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such agents.

Hayfever Relief Spray will control seasonal allergic rhinitis in most cases. However, an abnormally heavy challenge of summer allergies, may in certain situations, necessitate appropriate additional therapy, especially to control eye symptoms.

Systemic effects of nasal corticosteroids may occur particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations.

Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).

Growth retardation has been reported in children receiving nasal corticosteroids at licensed doses. It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid, if possible, to the lowest dose at which effective control of symptoms is maintained.

In addition, consideration should be given to referring the patient to a paediatric specialist. Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

Hayfever Relief Spray contains benzalkonium chloride which may cause irritation or swelling inside the nose especially if used for a long time. Visual disturbance Visual disturbance may be reported with systemic and topical corticosteroid use.

If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Hayfever Relief Spray is contra-indicated in patients with a history of hyper-sensitivity to any of the components.